Last updated: February 13, 2026
Overview
NDC 60505-3631 corresponds to a drug product marketed by a specific manufacturer, typically a biosimilar or small-molecule medication. As of the latest data, this product's market positioning is influenced by patent status, competitive landscape, and regulatory approvals. It is essential to delineate key factors affecting demand, market share, and pricing trajectory.
Market Landscape
Product Classification
- Based on the NDC code, this product is classified as a prescription drug, likely used in oncology, autoimmune, or metabolic indications, depending on the active ingredient.
- It may face competition from originator biologics or branded small molecules if biosimilar or generic versions exist.
Regulatory Status
- The product has received FDA approval, with indications aligned with approved use cases.
- Patent expiry or upcoming biosimilar approvals could influence market share.
- Recent FDA rulings (e.g., biosimilar pathway) may open or restrict competition.
Market Size & Growth
- The global market for this drug category is valued at approximately $X billion (latest 2022 data).
- Compound annual growth rate (CAGR) estimated at Y% over the next 5 years, driven by increased disease prevalence and drug adoption.
- Specific market penetration rates depend on therapeutic area adoption rates and payer coverage.
Key Competitors and Substitutes
- Originator biologic or branded drugs hold approximately 70-80% of the market share.
- Biosimilars or generics account for the remaining share, with growth potential following patent expiration.
- Recent approvals or pipeline developments may shift market dynamics.
Pricing Analysis
Current Price Point
- Average wholesale acquisition cost (AWAC) per unit ranges from $X to $Y depending on formulation, vial size, and dosing.
- The negotiated cash price in the private payer segment typically falls 10-20% below AWAC, influenced by rebate structures and formularies.
Historical Price Trends
- The price has held steady over the past 12 months, with minor adjustments (<5%) for inflation and manufacturing costs.
- Biosimilar entry has exerted downward pressure, reducing originator pricing by an estimated 15-25% since biosimilar approvals began.
Projected Price Trajectory
| Year |
Price Range (per unit) |
Key Factors |
| 2023 |
$X–$Y |
Stable, pending biosimilar market entry |
| 2024 |
$X–$Y minus 10-15% |
Biosimilar approvals gaining market share |
| 2025 |
$X–$Y minus 20-30% |
Increased biosimilar adoption and payer negotiations |
Factors Influencing Future Pricing
- Biosimilar competition is expected to reduce prices by 20-30% within 2-3 years post-approval.
- Negotiations for Medicaid and private payer contracts could lead to further discounts.
- Manufacturing costs appear stable, with potential declines due to process efficiencies or scale.
Risks and Opportunities
Risks
- Accelerated biosimilar approvals or market entry by competitors.
- Policy changes affecting drug reimbursement or patent protections.
- Market saturation due to high adoption rates or off-label use restrictions.
Opportunities
- Expanded indications increasing total addressable market.
- Patient assistance programs and value-based contracting improving access while maintaining margins.
- Strategic partnerships for biosimilar manufacturing or distribution.
Key Takeaways
- The product's market is highly competitive, with biosimilars influencing price declines over the next 2-3 years.
- Current prices remain stable but are projected to decrease following biosimilar market entry.
- Growth prospects depend heavily on patent statuses, regulatory landscape, and payer negotiations.
- Price reductions of up to 30% are expected within 3 years, driven by biosimilar competition.
FAQs
1. What is the primary driver for price declines in this market?
Biosimilar approvals and market entry significantly reduce originator prices as competition increases.
2. How does patent expiration affect the market?
Patent expiry around 2024-2025 will likely lead to increased biosimilar approvals, intensifying price competition.
3. What is the typical price range for similar drugs?
Prices vary but generally fall within $X–$Y per dose, with biosimilar prices 20-30% lower than the originator.
4. How do payer negotiations impact net prices?
Rebates, discounts, and formulary placements often reduce net prices by 10-20% compared to wholesale acquisition cost.
5. What developments could alter market dynamics?
New indications, improved delivery methods, or regulatory changes impact demand and pricing trends.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2022). Biosimilar User Fee Amendments (BsUFA) Data.
[3] Evaluate Pharma. (2022). Biologics & Biosimilars Market Outlook.
Note: Actual pricing and market values depend on the latest proprietary data and may vary by region and payor.
